A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER

  • Authors:
    • WJ GRADISHAR
    • DJ HARAF
    • PC HOFFMAN
    • AW RADEMAKER
    • MK FERGUSON
    • H GOLOMB
    • JD BITRAN
    • EE VOKES
  • View Affiliations

  • Published online on: September 1, 1994     https://doi.org/10.3892/or.1.5.957
  • Pages: 957-962
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment strategies for locally advanced nonsmall cell lung cancer have failed to significantly alter the survival of most patients. Treatment strategies utilizing, neoadjuvant chemotherapy and concurrent chemotherapy/radiation therapy have shown promise in some reports. Twenty-six consecutive patients with stage III, non-small cell lung cancer were treated over a 3 year period according to a strategy involving neoadjuvant chemotherapy (mitomycin, vinblastine, cisplatin [MVP]) followed by reassessment for surgical resection, followed by treatment with concomitant radiation therapy and chemotherapy (hydroxyurea [HU], 5-fluorouracil [5-FU]). Staging revealed stage IIIa disease in 15 patients and stage IIIb disease in 11 patients. Nine of 18 evaluable patients responded to MVP (50%) with 1 CR and 8 PRs. Only one of nine responders underwent surgical resection. Eleven of 19 patients receiving concomitant 5-FU, HU, and radiation therapy were evaluable for response. Two of 11 patients were converted to clinical CRs, and the remaining 9 patients had stable disease. Myelosuppression, mucositis and hand-foot syndrome were observed with 5-FU/HU/RT. Median survival for all patients is 10.5 months. One and 2-year survival is estimated at 36% and 27%, respectively. This clinical trial combining neoadjuvant chemotherapy with concurrent chemotherapy/radiation therapy is feasible. Select patients appeared to have a survival benefit however most patients failed to derive an improvement in clinical endpoints.

Related Articles

Journal Cover

September 1994
Volume 1 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
GRADISHAR W, HARAF D, HOFFMAN P, RADEMAKER A, FERGUSON M, GOLOMB H, BITRAN J and VOKES E: A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER. Oncol Rep 1: 957-962, 1994
APA
GRADISHAR, W., HARAF, D., HOFFMAN, P., RADEMAKER, A., FERGUSON, M., GOLOMB, H. ... VOKES, E. (1994). A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER. Oncology Reports, 1, 957-962. https://doi.org/10.3892/or.1.5.957
MLA
GRADISHAR, W., HARAF, D., HOFFMAN, P., RADEMAKER, A., FERGUSON, M., GOLOMB, H., BITRAN, J., VOKES, E."A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER". Oncology Reports 1.5 (1994): 957-962.
Chicago
GRADISHAR, W., HARAF, D., HOFFMAN, P., RADEMAKER, A., FERGUSON, M., GOLOMB, H., BITRAN, J., VOKES, E."A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER". Oncology Reports 1, no. 5 (1994): 957-962. https://doi.org/10.3892/or.1.5.957